In a significant move to bolster its presence in the North American life sciences market, Eurofins has agreed to acquire Element Materials Technology’s life sciences testing services business. This strategic acquisition, announced on the heels of a series of expansions by Eurofins, underscores the company’s commitment to strengthening its portfolio of services tailored to the pharmaceutical, biotechnology, and medical device industries. The acquisition is set to enhance Eurofins’ capabilities in providing comprehensive testing solutions, further solidifying its position as a leading provider of analytical testing services.
Element Materials Technology’s life sciences testing services business in North America has been at the forefront of providing critical services to the life sciences sector, including testing for pharmaceuticals, biopharmaceuticals, and medical devices. The integration of these services into Eurofins’ operations is expected to not only broaden the company’s service offerings but also deepen its expertise in regulatory compliance and quality assurance for life sciences clients.
The acquisition is part of Eurofins’ broader strategy to expand its global footprint and enhance its service capabilities through strategic investments and acquisitions. With this move, Eurofins aims to provide its clients with an even more comprehensive suite of testing and advisory services, leveraging the combined strengths of both organizations to drive innovation and compliance in the life sciences industry.
Original news story via Business Wire.